Article Sidebar
Keywords:
Adiponectin Cardiovascular Complications Diabetes Mellitus End Stage Renal Disease
Article Details
Issue
Section
Articles
Copyright belongs to The Arab Society of Nephrology and Renal Transplantation (ASNRT)
Main Article Content
Association between Low Adiponectin Level and Cardiovascular Complications in Diabetic and non Diabetic Patients with End Stage Renal Disease
Abstract
Introduction: Adiponectin is a collagen-like protein synthesized by adipose tissue that has anti-inflammatory and anti-atherogenic properties. We aimed to evaluate adiponectin levels in end stage renal disease (ESRD) patients with and without diabetes mellitus and its relation to the presence of cardiovascular complications (CVC).
Methods: The study included 20 healthy subjects who served as controls (group I), 20 non-diabetic ESRD patients without CVC (group IIA), 20 non-diabetic ESRD patients with CVC (group IIB), 20 diabetic ESRD patients without CVC (group IIIA) and 20 diabetic ESRD patients with CVC (group IIIB). Evaluation included mean arterial blood pressure (MABP), body mass index (BMI), fasting plasma glucose, fasting plasma insulin, homeostasis model assessment for insulin resistance (HOMA-IR), lipid profile, and serum adiponectin levels.
Results: Adiponectin level in the control group was 6.4±1.2 mcg/ml, and was significantly lower than both group II and III (P<0.01). Adiponectin was also significantly lower in group III compared to group II (11±3.9 versus 13.1±4.1 mcg/ml, P<0.01). Patients in group IIB were found to have a lower adiponectin level than group IIA (11.3±2.9 versus 14.9±4.5 mcg/ml, P < 0.01). Patients in group IIIB were also found to have a lower adiponectin level than group IIIA (9.0±2.5 versus 12.9±4 mcg/ml, P < 0.01). Adiponectin level had a significant positive correlation with high density cholesterol (HDL-C) and a significant negative correlation with MABP, BMI, plasma insulin, HOMA-IR, low density cholesterol (LDL-C), triglycerides and total cholesterol in all subgroups.
Conclusion: Adiponectin level was higher in ESRD patients compared to controls. Adiponectin level was lower in diabetic ESRD patients compared to non-diabetic patients, and lower in ESRD patients with CVC compared to patients without CVC.
Keywords: Adiponectin, Cardiovascular Complications, Diabetes Mellitus, End Stage Renal Disease
Methods: The study included 20 healthy subjects who served as controls (group I), 20 non-diabetic ESRD patients without CVC (group IIA), 20 non-diabetic ESRD patients with CVC (group IIB), 20 diabetic ESRD patients without CVC (group IIIA) and 20 diabetic ESRD patients with CVC (group IIIB). Evaluation included mean arterial blood pressure (MABP), body mass index (BMI), fasting plasma glucose, fasting plasma insulin, homeostasis model assessment for insulin resistance (HOMA-IR), lipid profile, and serum adiponectin levels.
Results: Adiponectin level in the control group was 6.4±1.2 mcg/ml, and was significantly lower than both group II and III (P<0.01). Adiponectin was also significantly lower in group III compared to group II (11±3.9 versus 13.1±4.1 mcg/ml, P<0.01). Patients in group IIB were found to have a lower adiponectin level than group IIA (11.3±2.9 versus 14.9±4.5 mcg/ml, P < 0.01). Patients in group IIIB were also found to have a lower adiponectin level than group IIIA (9.0±2.5 versus 12.9±4 mcg/ml, P < 0.01). Adiponectin level had a significant positive correlation with high density cholesterol (HDL-C) and a significant negative correlation with MABP, BMI, plasma insulin, HOMA-IR, low density cholesterol (LDL-C), triglycerides and total cholesterol in all subgroups.
Conclusion: Adiponectin level was higher in ESRD patients compared to controls. Adiponectin level was lower in diabetic ESRD patients compared to non-diabetic patients, and lower in ESRD patients with CVC compared to patients without CVC.
Keywords: Adiponectin, Cardiovascular Complications, Diabetes Mellitus, End Stage Renal Disease
